Beta 2 Adrenergic Receptor Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Beta 2 Adrenergic Receptor Agonist Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2023

Beta 2 adrenergic receptor agonists are a class of medications that activate the beta 2 adrenergic receptors in the body. These receptors are predominantly found in smooth muscle tissues, particularly in the lungs. The mechanism of action of beta 2 adrenergic receptor agonists involves binding to these receptors, which leads to relaxation of the smooth muscles in the airways, resulting in bronchodilation. This makes them particularly effective in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). According to the World Health Organization (WHO), respiratory conditions affect a significant number of people globally. In Europe, approximately 235 million people are affected by asthma, and it is estimated that COPD affects around 44 million individuals. In the United States, the Centers for Disease Control and Prevention (CDC) reports that around 25 million people have asthma, while over 16 million adults have been diagnosed with COPD.

The growth drivers of the beta 2 adrenergic receptor agonist market include the increasing prevalence of respiratory diseases, rising awareness and diagnosis rates, advancements in drug formulations and delivery systems, and the growing aging population. These factors contribute to the expanding market for beta 2 adrenergic receptor agonists, as they continue to be crucial medications in managing respiratory conditions and improving patients' quality of life. Companies such as AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Teva, Chiesi, Merck (MSD), Innoviva, Orion Corp, Vectura, Almirall, CuraSen Therap, Intech Biopharm, Evofem Biosci, Otsuka cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, AstraZeneca is one such company currently conducting a clinical trial of the drug Abediterol (AZD-0548) for treating Asthma.

Key Developments

  • In September 2019, GSK launched Anoro Ellipta for Chronic obstructive pulmonary disease in Italy
  • In September 2021, Boehringer Ingelheim launched Spiolto Respimat for Chronic obstructive pulmonary disease in France, Greece, Hungary, Portugal, Belgium, New Zealand, Israel, Germany, Sweden, Poland, Chile, Russia, Philippines, Netherlands, Czech Republic, Indonesia, Hong Kong, Argentina, Switzerland, Turkey, Mexico, Singapore, Ukraine

Approved Beta 2 Adrenergic Receptor Agonist molecules

  • Fluticasone propionate, salmeterol xinafoate inhalation powder
  • Budesonide, formoterol
  • Breo Ellipta (fluticasone furoate , vilanterol)
  • Onbrez (indacaterol)
  • Ventolin (albuterol)
  • Albuterol sulfate
  • Stiolto Respimat (olodaterol, tiotropium FDC)
  • Anoro Ellipta (umeclidinium, vilanterol)
  • Beclometasone, formoterol
  • Ultibro (glycopyrronium, indacaterol)
  • Striverdi Respimat (olodaterol)
  • Riarify (beclometasone, formoterol, glycopyrrolate)
  • Albuterol sulfate inhalation aerosol
  • Levalbuterol
  • Flutiform (fluticasone, formoterol)
  • Breztri Aerosphere (budesonide, formoterol fumarate, glycopyrronium)
  • Trelegy Ellipta (fluticasone furoate, umeclidinium bromide, vilanterol)
  • Combivent (ipratropium, salbutamol)
  • Bevespi Aerosphere (formoterol, glycopyrrolate)
  • Dulera (mometasone, formoterol)
  • Foradil Aerolizer (formoterol dry powder inhaler)
  • Arformoterol
  • Terbutaline oral
  • Atectura Breezhaler (indacaterol, mometasone furoate)
  • Berodual N (ipratropium bromide, fenoterol hydrobromide)
  • Proventil (albuterol)
  • Atimos (formoterol hydrofluoroalkane inhaler) , Chiesi ,
  • Bufomix Easyhaler (budesonide, formoterol dry powder inhaler)
  • Oxis Turbuhaler (formoterol)
  • Xopenex HFA (levalbuterol tartrate)
  • Oxeze Turbuhaler (formoterol dry-powder inhaler)
  • Enerzair Breezhaler (glycopyrrolate, indacaterol, mometasone)
  • Fenoterol
  • Airsupra (budesonide, salbutamol)
  • DuoResp Spiromax (budesonide, formoterol)
  • Formoterol fumarate
  • Advair HFA (salmeterol xinafoate, fluticasone propionate inhalation aerosol)
  • HOKUNALIN patch (tulobuterol)
  • Serevent Diskhaler (salmeterol dry-powder inhaler)
  • Ventmax SR (salbutamol sulphate)
  • Albuterol inhaled aerosol
  • Salmeterol, fluticasone easyhaler
  • Alenia (budesonide, formoterol)
  • Salbutamol, beclomethasone
  • Bambec (bambuterol)
  • Combivent Respimat (ipratropium, albuterol metered spray inhalation)
  • Edsivo (celiprolol)
  • Formoterol, fluticasone
  • Meptin Tablet (procaterol)
  • Proair digihaler (albuterol sulfate)
  • Duoneb (ipratropium bromide, albuterol sulfate)
  • Ipralev (ipratropium, levosalbutamol)
  • ProAir Respiclick (albuterol sulfate inhalation powder)
  • Synflutide (fluticasone, salmeterol)
  • Ciclesonide, formoterol
  • AirDuo Digihaler (salmeterol, fluticasone proprionate)
  • Buventol Easyhaler (salbutamol dry-powder inhaler)
  • Chronodyne (terbutaline vaginal gel)
  • Meptin Swinghaler (procaterol)

Beta 2 Adrenergic Receptor Agonist Pipeline Molecules

  • Formoterol fumarate  (PT005)
  • Vilanterol (GW642444H)
  • Budesonide, formoterol (PT009)
  • Batefenterol (GSK961081)
  • Abediterol (AZD-0548)
  • Albuterol sulfate metered dose inhaler (PT007)
  • Salmeterol xinafoate (LIPO-202)
  • AZD3199
  • Salmeterol xinafoate, fluticasone propionate (LIPO 102)
  • Albuterol inhalational powder (A006 DPI)
  • Bedoradrine (KUR-1246)
  • Navafenterol (AZD8871)
  • Salbutamol (ASF-1096)
  • Nadolol (CST-107)
  • CST-2032
  • Budesonide, carmmonteoterol (CHF 5188)
  • Fluticasone, batefenterol (FF, GSK-961081)
  • Nadolol oral (INV102 oral)
  • Budesonide, formotenol (SYN010)
  • ATR-258
  • AZD8999
  • CHF6366
  • Albuterol sufate DPI (TBS-7)
  • Terbutaline modified-release (SKP-1052)

Clinical Activity and Development of Beta 2 Adrenergic Receptor Agonist

In the Beta 2 Adrenergic Receptor Agonist space, more than 30 companies are conducting around 800 clinical trials in this category of drugs. For instance,

  • In April 2023, GSK presented interim efficacy data of Breo Ellipta from a phase III captain trial in asthma at the 117th International Conference of the American Thoracic Society
  • In May 2022, GlaxoSmithKline completed a phase III trial of Fluticasone furoate in Asthma (In children, In adolescents) in the US, Argentina, China, Canada, Japan, Mexico, Romania, Russia, South Africa, Poland, Lithuania, Hungary, Bulgaria, Italy, Germany, and Spain

Product Name

Total Studies

Formoterol fumarate  (PT005)

106

Vilanterol (GW642444H)

29

Budesonide, formoterol (PT009)

15

Batefenterol (GSK961081)

13

Abediterol (AZD-0548)

10

Albuterol sulfate metered dose inhaler (PT007)

7

Salmeterol xinafoate (LIPO-202)

7

AZD3199

6

Salmeterol xinafoate, fluticasone propionate (LIPO 102)

6

qAlbuterol inhalational powder (A006 DPI)

5

Bedoradrine (KUR-1246)

5

Navafenterol (AZD8871)

5

Salbutamol (ASF-1096)

5

Nadolol (CST-107)

4

CST-2032

3

Budesonide, carmmonteoterol (CHF 5188)

3

Fluticasone, batefenterol (FF, GSK-961081)

3

Nadolol oral (INV102 oral)

3

Target Indication Analysis of Beta 2 Adrenergic Receptor Agonist

The primary target indication for beta 2 adrenergic receptor agonist drugs is the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). These medications are specifically designed to provide bronchodilation by activating the beta 2 adrenergic receptors in the smooth muscles of the airways. By doing so, they help to relax and widen the air passages, making breathing easier for individuals with respiratory disorders. beta 2 adrenergic receptor agonists are commonly prescribed as short-acting or long-acting inhalers, and they play a crucial role in controlling symptoms, reducing the frequency and severity of asthma attacks, and improving overall lung function in patients with COPD.

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

Beta 2 Adrenergic Receptor Agonist drugs are used in the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The growth drivers of the beta 2 adrenergic receptor agonist market in the US include the increasing prevalence of respiratory diseases, a large population affected by asthma and COPD, technological advancements in drug delivery systems, and the presence of well-established healthcare infrastructure.

The major players in this space are AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Teva, Chiesi, Merck (MSD), Innoviva, Orion Corp, Vectura, Almirall, CuraSen Therap, Intech Biopharm, Evofem Biosci, Otsuka.

One of the restraints of the beta 2 adrenergic receptor agonist drug market is the potential for side effects associated with these medications, such as tremors, increased heart rate, and decreased potassium levels. These side effects may limit their use in certain patient populations or require close monitoring during treatment. Additionally, the emergence of alternative treatment options and the availability of generic versions of beta 2 adrenergic receptor agonists may pose a competitive challenge to the market, impacting pricing and market share.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

Key Market Players

  • AstraZeneca
  • GSK
  • Novartis
  • Boehringer Ingelheim
  • Teva
  • Chiesi
  • Merck (MSD)
  • Innoviva
  • Orion Corp
  • Vectura
  • Almirall
  • CuraSen Therap
  • Intech Biopharm
  • Evofem Biosci
  • Otsuka
  • Sosei
  • Theravance Biopharma
  • ASKA Pharma
  • Abbott
  • Acer Therap
  • Acerus
  • Ache Lab
  • Amphastar
  • Ardana Biosci
  • Atrogi
  • Avillion
  • Catalent
  • Chronic Airway Therap
  • Cipher
  • Covis Pharma
  • Kissei
  • Kyorin
  • Maruho
  • MediciNova
  • Mundipharma
  • Neutec
  • Nitto Denko
  • Sanofi
  • Sumitomo Pharma
  • Takeda
  • Viatris

Related Industry Reports